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Cathepsin D is a ubiquitously expressed lysosomal protease that is involved in proteolytic degradation, cell invasion,
and apoptosis. In mice and sheep, cathepsin D deﬁciency is known to cause a fatal neurodegenerative disease. Here,
we report a novel disorder in a child with early blindness and progressive psychomotor disability. Two missense
mutations in the CTSD gene, F229I and W383C, were identiﬁed and were found to cause markedly reduced
proteolytic activity and a diminished amount of cathepsin D in patient ﬁbroblasts. Expression of cathepsin D
mutants in cathepsin D5/5 mouse ﬁbroblasts revealed disturbed posttranslational processing and intracellular tar-
geting for W383C and diminished maximal enzyme velocity for F229I. The structural effects of cathepsin D mutants
were estimated by computer modeling, which suggested larger structural alterations for W383C than for F229I.
Our studies broaden the group of human neurodegenerative disorders and add new insight into the cellular functions
of human cathepsin D.
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Cathespin D (CatD) belongs to the pepsin family of pro-
teases and is one of the most studied aspartic proteases.
It has been implicated in diverse biological processes.
CatD promotes invasion and proliferation of cancer
cells1 but is also involved in caspase-independent apo-
ptosis.2,3 Increased concentrations of CatD are found
during ischemic, inﬂammatory, and regenerative pro-
cesses, such as coronary heart disease,4 inﬂammatory
bowel disease,5 wound healing, and epidermal differ-
entiation.6 CatD is a major component of lysosomes and
functions as a highly active endopeptidase with an op-
timum pH between 3.0 and 5.0. CatD preferentially
cleaves peptide bonds that are ﬂanked by bulky hydro-
phobic amino acids and is strongly inhibited by pepstatin
A (inhibition constant nM). Human CatD isK p 1–4i
synthesized and translocated into the endoplasmic retic-
ulum (ER) as an inactive precursor proenzyme (53 kDa),
processed into an enzymatically active, intermediate pro-
enzyme (48 kDa), and ﬁnally converted in the lysosomal
compartment into a noncovalently associated two-chain
form with an N-terminal 15-kDa light chain and a C-
terminal 33-kDa heavy chain.7,8
Targeted disruption of the Ctsd gene in mice leads to
weight loss in the 3rd wk of life that is associated with
progressive atrophy of the intestinal mucosa. Massive
intestinal necrosis and profound destruction of lympho-
cytes in the spleen and thymus are found just before the
mice die in a state of anorexia at age 4 wk.9 In addition,
CatD-deﬁcient mice develop seizures and progressive ret-
inal atrophy, which leads to blindness. Lysosomal stor-
age of an autoﬂuorescent material, ceroid lipofuscin, is
found in neurons.10 Inactivation of theDrosophilaCatD
homologue causes age-dependent neurodegeneration
and also progressive neuronal accumulation of autoﬂuo-
rescent storage material.11 In sheep, a naturally occurring
missense mutation in the active-site aspartate (D293N)
of ovineCtsd results in early neurodegeneration.Because
of the autoﬂuorescent neuronal storage material, the dis-
ease was subsequently named “congenital ovine neuronal
ceroid lipofuscinosis” (CONCL [MIM *116840]).12
Recently, a second natural animal model of CatD in-
sufﬁciency was discovered in American bulldogs.13 Af-
fected dogs had 36% of the CatD-speciﬁc enzymatic
activity found in control dogs, and they presented with
a milder phenotype than CatD-deﬁcient mice and sheep.
Similar to these animal models, all currently known hu-
man neuronal ceroid lipofuscinosis (NCL) forms are
characterized by developmental regression, visual loss,
and epilepsy in addition to the name-giving accumula-
tion of autoﬂuorescent lysosomal storage material. At
present, six different disease genes have been identiﬁed
for human NCL: CLN1, CLN2, CLN3, CLN5, CLN6,
and CLN8.14,15
We screened a group of 25 infants and children with
a nonidentiﬁed genetic cause of an NCL-like disorder
and found the ﬁrst case of human CatD deﬁciency. We
determined the molecular mechanisms and functional
consequences of two missense mutations in the human
CTSD gene, and, in doing so, have extended our un-
derstanding of the biological functions of human CatD.
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Material and Methods
Material
Cell culture medium (Dulbecco’s modiﬁed Eagle medium
[DMEM]), zeocin, hygromycin, Lipofectamin 2000, and Taq
DNA polymerase were purchased from Invitrogen. Oligonu-
cleotides were synthesized byMWG-Biotech. For ampliﬁcation
of genomic DNA fragments of CTSD, the primer combination
hCDgDNA6960F (5′-GTGTAAACCGAGCCCTGATGACTT-3′)
and hCDgDNA7525R (5′-CAGCAGCAGGGAGGGGGCAGC-
ACT-3′) and the primer combination hCDgDNA10788F (5′-GGG-
GAGCCCCAAGGCCACCACTA-3′) and hCDgDNA11224R
(5′-CTCGGCGAAGCCCACCCTGTTGTT-3′) were used. For
ampliﬁcation of the CTSD cDNA fragments, the primer com-
bination hCDcDNA526F (5′-CGTGAAGAATGGTACCTCG-
TTTGA-3′) and hCDcDNA1319R (5′-CAGTGTAGTAGCG-
GCCGATGAAGAC-3′) was used. [a-32P]dCTP, [35S]methio-
nine, and molecular-weight protein markers were obtained
from Amersham Biosciences. Restriction enzymes were sup-
plied by New England BioLabs. Goat anti-human CatD an-
tibody and rabbit anti-mouse CatD antibody were a generous
gift from Professor Kurt von Figura (University of Go¨ttingen).
Rat anti-mouse lysosomal-associated membrane protein 1
(LAMP-1) antibody was acquired from the Developmental
Studies Hybridoma Bank (University of Iowa, Iowa City).
Biotin SP–conjugated donkey anti-goat antibody, peroxidase-
conjugated donkey anti-goat antibody, and peroxidase-con-
jugated streptavidin were purchased from Jackson Immuno-
Research Lab. For western blotting, peroxidase staining was
done with tetramethyl benzidine (TMB) substrate (Seramun).
Alexa Fluor 488 donkey anti-goat antibody and Alexa Fluor
546 goat anti-mouse and goat anti-rat antibodies were ob-
tained from Molecular Probes. The BigDye terminator kit was
used for semiautomated sequencing, in accordance with the
recommendations of the manufacturer (Perkin Elmer Applied
Biosystems). RNA was isolated from patient ﬁbroblasts with
the RNeasy kit as described by the manufacturer (Qiagen).
Total RNAwas fractionated by agarose-formaldehyde gel elec-
trophoresis, the gel was blotted onto a Hybond-XL membrane
(Amersham Biosciences), and the northern blot was hybridized
in accordance with standard procedures by use of the Nick
Translation System (Invitrogen) and the QuickHyb hybridi-
zation solution (Stratagene). The hybridization of RNA was
performed with two independent control RNAs that showed
very similar CatD expression. For cDNA synthesis, the Su-
perscript III First-Strand Synthesis System (Invitrogen) was
used. The substrate MOCAc-GKPIIFFRLK(Dnp)-R-NH2 was
obtained from Calbiochem. All other reagents were purchased
from Sigma-Aldrich.
The Patient
A patient with two heterozygous mutations in CTSD was
identiﬁed from a total of 25 pediatric patients showing symp-
toms of an unidentiﬁed, NCL-like neurodegenerative disease
including motor and visual disturbances. This group of pa-
tients was screened for possible NCL diseases. In patient ﬁ-
broblasts, activities for palmitoyl protein thioesterase 1 and
tripeptidyl peptidase 1 were normal, whereas CatD activity
was clearly reduced. Sequencing the coding regions of CTSD
resulted in the identiﬁcation of the missense mutations
g.6517TrA and g.10267GrC, whereas no pathogenic base
alterations were revealed in the CLN3, CLN5, CLN6, and
CLN8 genes.
After a normal early psychomotor development, the patient
ﬁrst showed neurodegenerative symptoms—in particular,
ataxia and visual disturbances—at early-school age. The ocular
fundus was found to show retinitis pigmentosa, and cranial
magnetic resonance imaging (MRI) scans revealed cerebral and
cerebellar atrophy. In the course of disease, she developed pro-
gressive cognitive decline, loss of speech, retinal atrophy, and
loss of motor functions. Now, at age 17 years, she is wheel-
chair bound and severely mentally retarded. Until now, there
has been no evidence of hematological disease, immunodeﬁ-
ciency, intestinal abnormalities, or dystrophia. In fact, because
of immobilization, the patient has become overweight during
the past few years.
Expression of Wild-Type CatD and Mutants in CatD/
Mouse Fibroblasts and Flp-In 3T3 Cells
CTSD cDNA was received from the IMAGE consortium
(RZPD clone ID IRAUp969A1048D6) and was cloned into
the expression vectors pcDNA3.1/Zeo and pEF5/FRT/V5-D-
TOPO (Invitrogen). Site-directed mutagenesis was performed
using a QuickChange site-directed mutagenesis kit (Strata-
gene), in accordance with the supplier’s protocol. All ﬁnal con-
structs were veriﬁed by semiautomated sequencing.
CatD/ mouse ﬁbroblasts and Flp-In 3T3 cells were seeded
on 35-mm plates at a density of cells/well in DMEM52# 10
supplemented with fetal calf serum (FCS) at 37C and 5%
CO2. After 24 h of culturing, the cells were transfected with
2 mg of plasmid and 5 ml of Lipofectamin 2000 in 0.5 ml of
Opti-MEM. The medium was replaced with DMEM supple-
mented with FCS after 6 h of incubation. Selection with zeocin
or hygromycin was started 48 h after transfection, and stable
clones were achieved after 14 d of selection. Cellular homog-
enates from individual clones were assayed for CatD activity
by use of the substrate MOCAc-GKPIIFFRLK(Dnp)-R-NH2,
as described elsewhere.16 Alternatively, cell lysates were ana-
lyzed by western blotting with anti-human CatD antibody. The
western-blotting experiments (ﬁg. 1B and 1C) were repeated
twice and led to very similar results.
Kinetic Analysis of Wild-Type and Mutant CatD
in Cell Lysates
For kinetic studies, 0.5 mg of cellular lysates were incubated
with 1.3, 2, 3.3, 6.7, 10, 13.3, 23.3, 33.3, and 45 mM of
substrate MOCAc-GKPIIFFRLK(Dnp)-R-NH2. Reaction ve-
locities were measured at deﬁned time intervals with a micro-
plate reader (Synergy HT [BIO-TEK Instruments]). Linear
phase velocities were plotted against the substrate concentra-
tions; Km and Vmax were calculated by nonlinear regression
using the equation , where V is linearVp V # [S]/(K  [S])max m
phase velocity, Vmax is maximal enzyme velocity, [S] is the sub-
strate concentration, andKm is theMichaelis-Menten constant.
Data obtained from one of two independent experiments were
measured in triplicate, and the means and SDs were plotted.
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Figure 1 Expression of human mutant and wild-type CatD. A,
Northern-blot analysis of CatD mRNA expression. Five micrograms
of total RNA puriﬁed from control ﬁbroblasts and patient ﬁbroblasts
was fractionated by agarose-formaldehyde gel electrophoresis, was
blotted, and then was hybridized with a 32P-labeled CatD-speciﬁc
probe. The amount of CatD-speciﬁc mRNA was similar for control
and patient RNA, and no additional transcript was detectable in the
patient. The quality of mRNA was controlled by equal expression
levels for glyceraldehyde 3-phosphate dehydrogenase (GAPDH). B,
Immunodetection of CatD in control and patient ﬁbroblasts. Cell ho-
mogenates (50 mg protein per lane) from control and patient human
skin ﬁbroblasts were separated by SDS-PAGE, were transferred to
nitrocellulose membrane, and were incubated with goat anti-human
CatD antibody, then with biotin SP–conjugated donkey anti-goat an-
tibody, and ﬁnally with peroxidase-conjugated streptavidin. The blot
was stained with TMB substrate to visualize the 53-kDa proenzyme
precursor and the 33-kDa heavy chain of mature CatD. The 33-kDa
band of patient cells has only 15% of the intensity of band for control
cells. The level of b-actin expression is equal for both. C, Expression
of human wild-type (wt) CatD and mutants in CatD/ mouse ﬁbro-
blasts. Lysates (30 mg protein per lane) from CatD/mouse ﬁbroblasts
stably transfected with either vector alone or constructs containing
human wild-type CatD or mutant F229I and W383C CatD were sub-
jected to SDS-PAGE, were transferred to nitrocellulose membrane, and
were stained with TMB substrate after incubation with goat anti-
human CatD antibody and peroxidase-conjugated donkey anti-goat
antibody. No immunostaining was detectable for vector-transfected
cells. All others showed immunoreactivity for the 53-kDa CatD pre-
cursor. Wild type–transfected cells had the strongest signal for the 33-
kDa heavy chain of mature CatD, mutant F229I showed about 50%
of the intensity of the wild type, and no 33-kDa protein was detectable
for mutantW383C. The positions of the precursor proenzyme (prepro)
and the heavy chain of mature CatD are indicated. D, Metabolic la-
beling of human wild-type (wt) and mutant CatD. Vector-transfected
CatD/ cells and CatD/ cells transfectedwith humanwild-typeCatD
or mutant F229I and W383C CatD were metabolically labeled with
[35S]Met for 30 min and were chased for 30 min and 4 h in DMEM
supplemented with 10% (v/v) FCS. The CatDwas immunoprecipitated
from cell lysate using goat anti-human CatD antibody in combination
with pansorbin cells and was resolved on SDS-PAGE. Mutant F229I
is incompletely processed to the 33-kDa heavy chain of the mature
protease when compared with wild-type CatD, whereas mutant
W383C is hardly processed at all. After addition of E64 and leupeptin
(E64Leu), the intensity of the 33-kDa heavy chain slightly decreased
for all three constructs.
Metabolic Labeling and Immunoprecipitation of Wild-Type
and Mutant CatD
CatD/ mouse ﬁbroblasts stably transfected with vector,
wild-type CatD, and F229I or W383C mutant CatD were
grown to 70% conﬂuence and then were washed twice with
methionine-free DMEM (Invitrogen); were incubated at 37C
for 1 h in the same medium, with or without proteinase in-
hibitor E64 (18 mM) and leupeptin (10 mM); and then were
incubated again for 30 min in the same medium supplemented
with 100 mCi/ml [35S]Met (Amersham Biosciences). The ra-
dioactive medium was removed. Cells were washed twice with
Hank’s balanced salt solution and were chased in DMEM
supplemented with FCS with or without proteinase inhibitor
E64 (18 mM) and leupeptin (10 mM). At 30 min and 4 h, cells
were washed three times with cold PBS and were solubilized
in cold Tris-buffered saline with 0.1% TX-100 and a protease
inhibitor cocktail. After precipitation of DNA with protam-
insulfate (0.3 mg/ml), the supernatant was adapted to an im-
munoprecipitation buffer containing 150 mM NaCl, 10 mM
NaH2PO4/K2HPO4 (pH 7.4), 0.5% Triton-X 100, 0.3% so-
dium deoxycholate, 0.2% SDS, 1% BSA, and proteinase in-
hibitor mix (Sigma-Aldrich). The supernatants were centri-
fuged at 13,000 g for 10 min and were incubated for 4 h with
1/10 volume of preimmune serum and Pansorbin cells (Calbio-
chem). The suspension was centrifuged at 20,000 g for 15 min,
and the supernatant was incubated overnight with 1/20 volume
of goat anti-human CatD antibody and with 1/2 volume of
washed Pansorbin cells. The suspension was centrifuged again
and washed three times with immunoprecipitation buffer.
The proteins bound to the anti-CatD antibody were separated
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from Pansorbin cells by boiling in sample buffer containing
60 mM Tris (pH 6.8), 25% glycerol, 2% SDS, 14 mM 2-
mercaptoethanol, and 0.1% bromphenol blue. The denatured
proteins were subjected to SDS-PAGE by use of the Laemmli
method. The gels were ﬁxed in an aqueous solution of 10%
acetic acid and 50% methanol, were soaked for 30 min in
Amplify solution (Amersham Biosciences), were vacuum-dried
at 60C, and were analyzed by quantitative radioactive im-
aging. The pulse chase was performed four times; displayed is
one representative experiment (ﬁg. 1D).
Electron Microscopy
A skin biopsy specimen from the patient was taken from
the axilla and was immediately ﬁxed in 2.5% glutaraldehyde
and postﬁxed in buffered 1% osmium tetroxide for 1 h. After
two 5-min rinses in PBS, the nerve segments were dehydrated
in graded concentrations of alcohol (50%, 70%, 80%, 96%,
and 100%), were incubated twice for 20 min in propylene
oxide, and were embedded in Araldite. Semithin sections (1
mm) were stained with toluidine blue. Thin sections, contrasted
with uranylacetate and lead citrate, were examined with a
Zeiss EM 10B electron microscope. Patient lymphocytes were
puriﬁed from whole blood by use of Ficoll separation, were
ﬁxed in 2.5% glutaraldehyde, and then were processed as de-
scribed for the skin biopsy. A total of 250 lymphocytes were
examined for intracellular inclusions.
Immunoﬂuorescent Microscopy
Flp-In 3T3 cells and CatD/ mouse ﬁbroblasts stably ex-
pressing wild-type or mutant CatD were grown on coverslips
to 80% conﬂuence. The cells were washed twice with PBS and
were ﬁxed with 3% paraformaldehyde in PBS for 20 min at
37C. Cells were washed again four times with PBS and then
were permeabilized and blocked with 5 mg/ml saponin in PBS
for 1 h at room temperature. Subsequently, the permeabilized
cells were incubated with primary antibodies, goat anti-human
CatD antibody, and rabbit anti-mouse CatD or rat anti-mouse
LAMP-1 antibody for 2 h at a dilution of 1:200 in PBS con-
taining 1 mg/ml saponin. After three washes with PBS, cells
were incubated with the appropriate secondary antibodies con-
jugated with Alexa Fluor 488 or 546 for 1 h in the dark. Flp-
In 3T3 cells were costained with anti-human CatD antibody
and anti-mouse CatD antibody, and CatD/mouse ﬁbroblasts
were costained with anti-human CatD antibody and anti-
mouse LAMP-1 antibody. Finally, coverslips were mounted on
object glasses with Fluoromount medium (Polysciences). The
ﬂuorescence was viewed using a Leica NTSC laser confocal
microscope (Leica) in sequential scan mode. At least 50 cells
per coverslip were examined under the microscope, and rep-
resentative cells were photographed. The transfection and
staining experiments with the Flp-In 3T3 cells and those with
the CatD/ mouse ﬁbroblasts gave similar results; the ex-
pression level was only slightly higher in the CatD/ mouse
ﬁbroblasts.
Sequence Alignment and Molecular Modeling
Amino acid sequences from members of the pepsin family
of peptidases were retrieved from the MEROPS database and
were aligned using the program CLUSTALW with the protein
weight matrix GONNET. The crystal structure of CatD (Pro-
tein Data Bank ID 1LYA)8 was used as a template for modeling
of the described variants. Model building was done with Swiss-
PdbViewer,17 version 3.7. Energy minimizations and initial mo-
lecular dynamics simulations were performed using the AM-
BER 8 package.18 Molecular dynamics were calculated at 300
K with explicit solvent for up to 1.9 ns until the root mean
SDs of coordinates remained constant. Images were created
using the program PyMOL,19 version 0.98.
Results
Identiﬁcation of a Patient Compound Heterozygous
for Two Missense Mutations in the CTSD Gene
In a group of 25 infants and childs with an uniden-
tiﬁed, NCL-like neurodegenerative phenotype, we iden-
tiﬁed a child with two mutations (g.6517TrA and
g.10267GrC) in exons 5 and 9 of the CTSD gene (ﬁg.
2). The ﬁrst mutation results in the amino acid substi-
tution F229I of the CatD precursor proenzyme (which
corresponds to F165I of the mature CatD); the second
mutation causes the amino acid replacement W383C
(which corresponds to W319C of the mature CatD).
Mutational analyses of the parents showed that muta-
tion F229I was derived from the mother, and mutation
W383C from the father. No further genetic alterations
were detected in the CTSD coding sequences of the af-
fected child and her parents. DNA analyses of 110 con-
trols revealed neither of the two mutations.
Alignment of mature human CatD with other active
peptidases from humans (pepsin A and renin), fungi
(saccharopepsin, mucorpepsin, and oryzepsin), sporozoa
(plasmepsin), and plants (CDR1 g.p.) demonstrated
highly conserved regions within the pepsin family of pep-
tidases (ﬁg. 3). The residue F229 (F183 in ﬁg. 3) belongs
to a group of 15 aa (of the total 389 aa positions dis-
played in ﬁg. 3) that are strictly conserved among the
members of this protein family. In contrast, residue
W383 (W358 in ﬁg. 3) is conserved among all 12 human
pepsin peptidases and nearly all other mammalian mem-
bers of this family but is not conserved within pepsin
peptidases from more distantly related species.
Electron Microscopic Illustration of Storage Material
in Schwann Cells
Ultrastructural examination of the skin biopsy ma-
terial from the patient revealed pathological inclusions
in nonmyelinated Schwann cells. Within the cytoplasm
of these Schwann cells, two main types of pathological
inclusions were found—namely, granular osmiophilic-
like deposits and myelin-like lamellar structures (ﬁg. 4).
In comparison with the granular deposits found in pa-
tients with infantile NCL (CLN1 defect), these granular
inclusions appear more heterogeneously and are less
abundant within cells. The indicatedmyelin-like lamellar
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Figure 2 Sequencing data of the two CTSD mutations g.6517TrA and g.10267GrC. By use of genomic DNA templates and either the
primer combination hCDgDNA6960F and hCDgDNA7525R or hCDgDNA10788F and hCDgDNA11224R, PCR fragments of the human
CTSD gene were ampliﬁed and sequenced with both primers independently. The g.6517TrA allele was detected in the mother, the g.10267GrC
allele in the father. The patient is compound heterozygous for both alleles. Ampliﬁcation of CTSD cDNA fragments of the patient (with primers
hCDcDNA526F and hCDcDNA1319R) disclosed the presence of the c.685TrA and c.1149GrC alleles in heterozygous form, conﬁrming the
results obtained from the sequencing of genomic DNA. The mutations c.685TrA and c.1149GrC result in missense mutations F229I and
W383, respectively, of the precursor proenzyme of human CatD (pre) and correspond to amino acid exchanges F165I and W319C, respectively,
of the mature human CatD (mat).
structures are less speciﬁc for NCL diseases because these
inclusions are also found in other storage diseases, such
as the mucopolysaccharidoses. Inclusions were not de-
tected in patient endothelial cells, ﬁbroblasts, and sweat
glands. In addition, no storage material was identiﬁed
in peripheral lymphocytes.
Reduced Stability, Delayed Processing, and Decreased
Enzymatic Activity Due to Missense Mutations F229I
and W383C in Human CTSD
Northern-blot analysis of patient RNA revealed levels
of CatD-speciﬁc transcription similar to those in a con-
trol sample (ﬁg. 1A). In contrast, western-blot analyses
of ﬁbroblast cell lysates from the patient showed amark-
edly decreased intensity of the 33-kDa band of mature
human CatD (ﬁg. 1B). The enzymatic activity measured
with a ﬂuorogenic substrate in the patient ﬁbroblasts
was decreased to 6.7% of the mean activity of 24 con-
trols (data not shown).
To investigate the functional consequences of mutant
CatD, we cloned the cDNAs of wild-type, mutant F229I,
and mutant W383C CatD in expression vectors and
stably expressed all three in CatD/ mouse ﬁbroblasts.
Western-blot analyses of cell lysates from transfected
cells disclosed a reduction (F229I) or absence (W383C)
of mature CatD (ﬁg. 1C). The reduced intensities of ma-
ture CatD indicate differences in processing of mutant
CatD. Therefore, we metabolically labeled cells with ra-
dioactive methionine for 30 min and performed pulse-
chase experiments. After the medium was exchanged
with a nonradioactive one, wild-type CatD as well as
mutants F229I and W383C were harvested after chase
Figure 3 Alignment of the mature human CatD with selected active peptidases of the pepsin family. The amino acid sequence of human
CatD (h-cathepsin D [aa 66–410]) was aligned with the following pepsin peptidases: human pepsin A and human renin (h-pepsin A [aa 63–
388] and h-renin [aa 73–406]), saccharopepsin (aa 78–405) from the yeast Saccharomyces cerevisiae, mucorpepsin (aa 76–424) from the fungus
Rhizomucor miehei, oryzepsin (aa 72–390) from the fungus Aspergillus oryzae, plasmepsin-1 (aa 126–449) from the sporozoan Plasmodium
falciparum, and CDR1 g.p. (aa 70–437) from the plant Arabidopsis thaliana. The sequences were retrieved from the MEROPS database and
were ordered by degree of homology. Identical amino acid residues are red, highly homologous amino acids are green, and low-homology amino
acids are blue. A characteristic feature of the pepsin family is the three amino acids D39, Y84, and D261 (asterisks [*]). In the h-cathepsin D
sequence, the 8-aa residues that separate the N-terminal light chain (97 aa) from the C-terminal heavy chain (244 aa) are underlined. During
the maturation of human CatD, these 8 aa are cleaved off. The positions of the two human missense mutations found in the patient are indicated
by arrows. F183 (F229 in the full-length h-cathepsin D sequence) is strictly conserved, W358 (W383 in the full-length h-cathepsin D sequence)
is merely conserved among human peptidases of the pepsin family (shown only for h-pepsin A and h-renin).
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Figure 4 Electron microscopy of storage material in Schwann
cells from skin biopsy specimen from the patient.A,At a magniﬁcation
of 20,000#, the image displays two nonmyelinated Schwann cells
(left) and one myelinated Schwann cell. The two nonmyelinated
Schwann cells contain various osmiophilic inclusions (arrow and ar-
rowhead). B, Displayed details at 50,000# magniﬁcation show two
types of intracellular inclusions: granular osmiophilic deposits (arrow-
head) and myelin-like lamellar structures (arrow).
Figure 5 Kinetic analysis of human CatD in patient ﬁbroblasts
and transfected CatD/ mouse ﬁbroblasts. The kinetic properties of
human CatD were measured for patient and control lysates (A) and
for lysates derived from CatD/ mouse ﬁbroblasts transfected with
wild-type CatD (wt) and mutant F229I (B). Increasing concentrations
of the ﬂuorogenic substrate MOCAc-GKPIIFFRLK(Dnp)-R-NH2were
incubated for 20 min with 0.5 mg of cell lysates each. The increase in
ﬂuorescence was plotted in relation to the concentration of substrate,
and Km and Vmax were determined by nonlinear curve ﬁtting. The
calculated Km values were similar to the reported value ( mM)K p 3.7m
determined with puriﬁed CatD. Vmax for patient lysates was only 7.7%
of that measured for control lysates. Lysates derived from CatD/
mouse ﬁbroblasts transfected with mutant F229I had a Vmax of 26%
when compared with those transfected with wild-type CatD.
times of 30 min and 4 h, respectively. Wild-type and
mutant CatD were immunoprecipitated from homoge-
nates of transfected cells with anti-human CatD anti-
bodies. The intensity of the 53-kDa precursor proen-
zyme CatD signal decreased with the length of chase
time (ﬁg. 1D). After 4 h of chase, all wild-type precursor
CatD was processed to the 33-kDa heavy chain of ma-
ture CatD, ∼96% of mutant F229I precursor, but only
∼7% of mutant W383C precursor. The addition of in-
hibitors of thiol and serine proteases (E64 and leupeptin)
resulted in increased intensity of the 53-kDa precursor
and slightly decreased intensity of the 33-kDa form. The
data thus indicate that the maturation of mutant F229I
is slightly delayed, whereas the processing of mutant
W383C is severely disturbed. Furthermore, they suggest
that the stability of the mature 33-kDa CatD protein is
not dependent on thiol or serine proteases.
The kinetic properties of CatD were determined for
patient and control ﬁbroblasts as well as for CatD/
mouse ﬁbroblasts transfected with wild-type CatD,
F229I and W383C mutant CatD, and the vector. In-
creasing concentrations of the ﬂuorogenic substrate
MOCAc-GKPIIFFRLK(Dnp)-R-NH2 were incubated
with equal amounts of cell lysates derived from the ﬁ-
broblasts. The measured reaction velocity was plotted
in relation to the concentration of substrate;Km andVmax
were determined by nonlinear curve ﬁtting (ﬁg. 5). The
Km value for patient ﬁbroblast lysates was comparable
to that of control lysates; however, Vmax for patient lys-
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ates was only 7.7% of that measured for control lysates
(ﬁg. 5A). Lysates derived from CatD/ mouse ﬁbro-
blasts transfected with wild-type CatD or mutant F229I
had comparable Km values as well, but Vmax for mutant
F229I was only 26% of that for wild-type CatD (ﬁg.
5B). For mutant W383C, only negligible substrate turn-
over could be detected, and the estimatedVmax was 0.3%
of that for wild-type CatD. No substrate cleavage was
detected for vector-transfected CatD/ mouse ﬁbro-
blasts (data not shown).
Intracellular Localization of Human CatD Mutants
Since both missense mutations were associated with
a signiﬁcant decrease in enzymatic activity, we compared
intracellular trafﬁcking of these human CatD mutants
with endogenous mouse CatD. We transfected 3T3 ﬁ-
broblasts with the cDNA of wild-type CatD, of mutant
F229I, and of mutant W383C. Single stable integration
of the expression cassettes was achieved using Flp-In
technology (Invitrogen). Human and mouse CatD were
immunolabeled with speciﬁc antibodies and were dou-
ble-stained with different secondary antibodies (ﬁg. 6).
We observed colocalization of anti-human CatD im-
munostaining with the anti-mouse CatD immunoreac-
tivity in the wild-type CatD and the F229I mutant. How-
ever, the W383C mutant showed a distinct staining
pattern. Only a small amount of mutant protein colo-
calized with mouse CatD, whereas most of the protein
was detected in nonlysosomal compartments, in partic-
ular within the ER (ﬁg. 6).
Corresponding experiments were performed with
CatD/ ﬁbroblasts transfected with wild-type ormutant
CatD. In this case, double-labeling was done with anti-
CatD antibody and anti–LAMP-2 antibody. These stud-
ies conﬁrmed the results obtained with transfected 3T3
ﬁbroblasts, showing lysosomal targeting of mutant
F229I but almost complete missorting ofmutantW383C
(ﬁg. 6; data shown only for mutant W383C).
Discussion
We report, for the ﬁrst time, that human CatD deﬁciency
is responsible for an autosomal recessive neurodegen-
erative disease that can manifest in early childhood. We
elucidated the underlying pathogenetic mechanisms
leading to functional loss of CatD. We studied protein
stability, posttranslational processing, enzymatic activ-
ity, and intracellular trafﬁcking of mutant CatD in het-
erologous expression systems.
CatD belongs to the pepsin family of peptidases that
presently comprises 442 known members from various
species. The strict conservation of F229 (F183 in ﬁg. 3)
underlines the crucial role of this residue in protease
function. Although residue W383 (W358 in ﬁg. 3) is
only conserved among human and mammalian pepsin
peptidases, it also must have a central role in CatD func-
tion, because mutant W383C leads to disturbed post-
translational processing, intracellular mistargeting, and
complete loss of proteolytic activity.
The results obtained by kinetic analyses of the human
CatD mutants were consistent with and complementary
to our ﬁndings from western blotting and pulse-chase
experiments. Almost none of the 53-kDa precursor pro-
enzyme of mutant W383C was processed to the mature
33-kDa peptidase, and hardly any enzymatic activity
was detectable (ﬁg. 1C and 1D). In contrast, mutant
F229I was correctly processed, although with some de-
lay, to an active peptidase. However, for mutant F229I,
the maximal enzyme velocity, Vmax, was only 26% the
amount for wild-type CatD (ﬁg. 5B). Since V pmax
(where kcat is the catalytic rate and [E]totalk # [E]cat total
is the total enzyme concentration), a smaller catalytic
rate as well as a diminished concentration of active en-
zyme may contribute to a decreased Vmax. The substan-
tially lower relativeVmax (7.7% of control) for the patient
ﬁbroblasts can be explained by the more profoundly
reduced concentration of active enzyme (ﬁgs. 1B and
5A). The second patient allele, W383C, had no signiﬁ-
cant residual enzymatic activity.
These ﬁndings were extended by experiments to in-
vestigate the subcellular localization of human wild-type
and mutant CatD. Heterologous expression of human
wild-type CatD, F229I mutant, and W383C mutant
demonstrated colocalization with mouse CatD for the
wild-type and F229I mutant CatD but major mistar-
geting for the W383C mutant. Together with the results
obtained from western blotting, pulse-chase experi-
ments, and kinetic studies, these data indicate a partial
loss of function for mutant F229I but an almost com-
plete loss of function for mutant W383C.
To further explain our experimental results, we pre-
dicted the conformational effects of F229I and W383C
mutations on wild-type CatD by computer modeling
based on the published x-ray structure of CatD8 (ﬁg. 7).
Preliminary molecular dynamics modeling suggested
larger structural alterations for the W383C mutant than
for the F229I mutant when compared with the wild-type
CatD structure (ﬁg. 7B). The ﬁrst 11 N-terminal aa of
mature CatD were shown to play a key role in pH-
dependent enzymatic activation of CatD.20 In the active
form of CatD, these amino acids build the ﬁrst strand
of the interdomain b-sheet. For neutral pH values, a
translocation of this strand inserting into the active-site
cleft is reported. Since F229 is located in the third strand
of the interdomain b-sheet, the reduced enzymatic ac-
tivity of mutant F229I might be explained by confor-
mational destabilization of the interdomain b-sheet (ﬁg.
7A). In addition to spatial changes, themutationW383C
may induce an alternative disulﬁde bond formation be-
Figure 6 Immunohistochemical localization of CatD mutants expressed in Flp-In 3T3 cells and CatD/ mouse ﬁbroblasts. The cells were
cultivated on glass coverslips. Washed and ﬁxed cells were costained with goat anti-human CatD antibody and secondary Alexa Fluor 488
conjugates (green) and with either rabbit anti-mouse CatD antibody or with mouse anti–protein disulﬁde isomerase (PDI) antibody and secondary
Alexa Fluor 546 conjugates (red). Vector, No signal for human CatD (hCD); only mouse CatD (mCD) is detectable with typical pattern (red).
WT, In 3T3 cells transfected with human wild-type CatD, human and mouse CatD colocalize. F229I, In 3T3 cells transfected with mutant
F229I CatD, human and mouse CatD colocalize. W383C, In 3T3 cells transfected with mutant W383C, the staining pattern for human CatD
(green) clearly differs from the signal for mouse CatD (red). However, minor signals show colocalization of mutant W383C with mouse CatD
(arrow). W383C, In CatD/ cells transfected with mutant W383C, the staining pattern for human CatD (green) mostly colocalizes with the
ER marker (red; anti-PDI antibody). The length of the bars corresponds to 8 mm.
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Figure 7 Structural effects of CTSD mutations. A, Cartoon structure of CatD showing the positions of mutations within the enzyme
domains. The active site is painted as a blue transparent surface. N and C labels indicate the N and C termini. The interdomain b-sheet of
CatD and its ﬂanking regions are in pink. This interdomain b-sheet plays a crucial role in the regulation of the enzymatic activity of CatD. Its
N-terminal strand (numbered 1) was shown to relocate at neutral pH and to insert into the active site cleft, effectively blocking substrate access
and keeping CatD in an inactive state.20 The residue F165 (F [red]) is located within strand 3 of the interdomain b-sheet. The N-terminal region
of strand 4 is ﬂanked by a short a-helix (aa G322 to Y329 [light green]) and by W319 (W [green]). B, Least-squares ﬁt for the three averaged
structures of wild-type CatD (blue), F165I (green), and W319C (red). N and C labels indicate the N and C termini. There are no major structural
differences between the backbone coordinates of wild-type CatD and the F165I mutant (average root mean SD 1.31 A˚). The comparison of
main-chain atom coordinates of wild-type CatD and those of the W319C mutant revealed higher differences (average root mean SD 2.02 A˚),
with a maximum deviation of ∼10.1 A˚ for G298 (red arrow). Note that amino acid residues are assigned on the basis of the published crys-
tal structure,8 and these residues correspond to residues of the full-length CatD precursor proenzyme sequence as follows: F165I p F229I,
G298 p G362, W319C p W383C, G322 p G386, and Y329 p Y393.
cause it is in close proximity to residue C290, which
forms a disulﬁde bond with C286.
Several animal models indicate that CatD deﬁciency
leads to fatal neurodegeneration. CatD-deﬁcient mice
and sheep exhibit cerebral atrophy and show neuronal
accumulation of autoﬂuorescent storage material—
mainly granular osmiophilic deposits.10,12 Our ﬁndings
are in agreement with these observations. The CatD-
deﬁcient patient described here has similar granular de-
posits in Schwann cells derived from skin biopsymaterial
and shows cerebral and cerebellar atrophy on cranial
MRI scans. However, whereas CatD-deﬁcient mice and
sheep die very early in the course of disease, this patient
presents a slower progress of disease, as does the recently
described bulldogs homozygous for the missense mu-
tation M199I.13 This might be because of signiﬁcant re-
sidual enzymatic activities measured for human mutant
F229I, as well as canine mutant M199I, versus a com-
plete loss of CatD function in mice and sheep. Therefore,
one may speculate about the more severe clinical phe-
notypes of human CatD deﬁciency that would be caused
by a complete loss of CatD function. The level of residual
proteolytic activity in distinct CatD mutants is likely to
determine the clinical phenotype of this neurodegener-
ative disease.
In summary, mutations in the human CTSD gene are
associated with a novel autosomal recessive disorder,
CatD-deﬁcient NCL. CatD has comparable functions in
humans and other mammals and seems to play a key
role in the homeostasis of neuronal structures. However,
the variation in phenotypic presentation of CatD deﬁ-
ciency between mice, sheep, dogs, and humans points
to additional species-speciﬁc differences in CatD func-
tion and thus disease mechanism. The study of other
cases of this novel human neurodegenerative disease will
further elucidate the pathology in CatD-related neuro-
degeneration and will promote attempts to design ther-
apeutic strategies for this devastating group of disorders.
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Web Resources
The URLs for data presented herein are as follows:
MEROPS—the Peptidase Database, http://merops.sanger.ac.uk/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm
.nih.gov/Omim/ (for CONCL)
Protein Data Bank, http://www.rcsb.org/pdb/
PyMOL, http://pymol.sourceforge.net/
References
1. Nomura T, Katunuma N (2005) Involvement of cathepsins in the
invasion, metastasis and proliferation of cancer cells. J Med Invest
52:1–9
2. Broker LE, Kruyt FA, Giaccone G (2005) Cell death independent
of caspases: a review. Clin Cancer Res 11:3155–3162
3. Liaudet-Coopman E, BeaujouinM, Derocq D, GarciaM, Glondu-
Lassis M, Laurent-Matha V, Prebois C, Rochefort H, Vignon F
(2005) Cathepsin D: newly discovered functions of a long-standing
aspartic protease in cancer and apoptosis. Cancer Lett (http://
www.sciencedirect.com/science/journal/03043835) (electronically
published July 18, 2005; accessed February 24, 2006)
4. Vivanco F, Martin-Ventura JL, Duran MC, Barderas MG, Blanco-
Colio L, Darde VM, Mas S, Meilhac O,Michel JB, Tunon J, Egido
J (2005) Quest for novel cardiovascular biomarkers by proteomic
analysis. J Proteome Res 4:1181–1191
5. Hausmann M, Obermeier F, Schreiter K, Spottl T, Falk W, Schol-
merich J, Herfarth H, Saftig P, Rogler G (2004) Cathepsin D is
up-regulated in inﬂammatory bowel disease macrophages. Clin
Exp Immunol 136:157–167
6. Egberts F, Heinrich M, Jensen JM, Winoto-Morbach S, Pfeiffer S,
Wickel M, Schunck M, Steude J, Saftig P, Proksch E, Schutze S
(2004) Cathepsin D is involved in the regulation of transglut-
aminase 1 and epidermal differentiation. J Cell Sci 117:2295–2307
7. Horst M, Hasilik A (1991) Expression and maturation of human
cathepsin D in baby-hamster kidney cells. Biochem J 273:355–
361
8. Baldwin ET, Bhat TN, Gulnik S, Hosur MV, Sowder RC 2nd,
Cachau RE, Collins J, Silva AM, Erickson JW (1993) Crystal
structures of native and inhibited forms of human cathepsin D:
implications for lysosomal targeting and drug design. Proc Natl
Acad Sci USA 90:6796–6800
9. Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann
H, Koster A, Hess B, Evers M, von Figura K, Peters C (1995)
Mice deﬁcient for the lysosomal proteinase cathepsin D exhibit
progressive atrophy of the intestinal mucosa and profound de-
struction of lymphoid cells. EMBO J 14:3599–3608
10. Koike M, Nakanishi H, Saftig P, Ezaki J, Isahara K, Ohsawa Y,
Schulz-Schaeffer W, Watanabe T, Waguri S, Kametaka S, Shibata
M, Yamamoto K, Kominami E, Peters C, von Figura K, Uchiyama
Y (2000) Cathepsin D deﬁciency induces lysosomal storage with
ceroid lipofuscin in mouse CNS neurons. J Neurosci 20:6898–
6906
11. Myllykangas L, Tyynela J, Page-McCaw A, Rubin GM, Haltia
MJ, Feany MB (2005) Cathepsin D-deﬁcient Drosophila recapit-
ulate the key features of neuronal ceroid lipofuscinoses.Neurobiol
Dis 19:194–199
12. Tyynela J, Sohar I, Sleat DE, Gin RM, Donnelly RJ, Baumann M,
Haltia M, Lobel P (2000) A mutation in the ovine cathepsin D
gene causes a congenital lysosomal storage disease with profound
neurodegeneration. EMBO J 19:2786–2792
13. Awano T, Katz ML, O’Brien DP, Taylor JF, Evans J, Khan S, Sohar
I, Lobel P, Johnson GS (2005) A mutation in the cathepsin D gene
(CTSD) in American bulldogs with neuronal ceroid lipofuscinosis.
Mol Genet Metab (http://www.sciencedirect.com/science/journal/
10967192) (electronically published December 28, 2005; accessed
February 24, 2006)
14. Hofmann SL, Peltonen L (2001) The neuronal ceroid lipofusci-
noses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The
metabolic and molecular bases of inherited disease, 8th ed. Mc-
Graw-Hill, New York, pp 3877–3894
15. Mole SE (2004) The genetic spectrum of human neuronal ceroid-
lipofuscinoses. Brain Pathol 14:70–76
16. Yasuda Y, Kageyama T, Akamine A, Shibata M, Kominami E,
Uchiyama Y, Yamamoto K (1999) Characterization of new ﬂuo-
rogenic substrates for the rapid and sensitive assay of cathepsin
E and cathepsin D. J Biochem (Tokyo) 125:1137–1143 (erratum
126:260)
17. Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-
PdbViewer: an environment for comparative protein modeling.
Electrophoresis 18:2714–2723
18. Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, Merz
KM Jr, Onufriev A, Simmerling C, Wang B, Woods RJ (2005) The
Amber biomolecular simulation programs. J Comput Chem 26:
1668–1688
19. DeLano WL (2002) The PyMOL molecular graphics system.
DeLano Scientiﬁc, San Carlos, CA
20. Lee AY, Gulnik SV, Erickson JW (1998) Conformational switching
in an aspartic proteinase. Nat Struct Biol 5:866–871
